• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution

Merck receives CRL from the FDA for TECOS study with sitagliptin

cphi-onlineApril 10, 2017

Tag: Merck , FDA

CRL relates to Merck's sNDA for Januvia, Janumet and Janumet XR.

Merck (MSD outside the US and Canada) has, announced that the FDA has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for Januvia (sitagliptin), Janumet (sitagliptin and metformin HCl) and Janumet XR (sitagliptin and metformin HCl extended-release).

With these applications, Merck is seeking to include data from TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) in the prescribing information of sitagliptin-containing medicines. Merck is reviewing the letter and will discuss next steps with the FDA.

Previous:Hikma enters into settlement agreement with Jazz for sodium oxybate

Next:Japan's Astellas pharma to acquire Belgium firm Ogeda

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Gan & Lee Pharmaceuticals is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial.

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Merck receives CRL from the FDA for TECOS study with sitagliptin | Pharmasources.com

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

You may like
More>>

Nabumetone (FDA)

Nabumetone (FDA)
99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Aciclovir (FDA)

Aciclovir (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Ivermectin (FDA)

Ivermectin (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service